Protagonist Therapeutics, Inc.
PTGX
Rang in aandelen
#2298
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aandeelprijs
$134.37
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$8.70B
Verandering (1 dag)
4.37%
Verandering (1 jaar)
75.15%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Categorie
Healthcare
EPS voor Protagonist Therapeutics, Inc. (PTGX)
EPS per June 2026 TTM: $1.22
Volgens de laatste financiële rapporten en de aandelenkoers van Protagonist Therapeutics, Inc. is de huidige EPS van het bedrijf (TTM) $1.22. Eind 2023 had het bedrijf een EPS van $-1.39, een daling ten opzichte van de EPS van 2022 die $-2.52 bedroeg.
EPS-geschiedenis van Protagonist Therapeutics, Inc. van 2014 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.22 | -72.71% |
| 2024 | $4.47 | -421.58% |
| 2023 | $-1.39 | -44.84% |
| 2022 | $-2.52 | -4.91% |
| 2021 | $-2.65 | 38.02% |
| 2020 | $-1.92 | -35.57% |
| 2019 | $-2.98 | 71.26% |
| 2018 | $-1.74 | -16.75% |
| 2017 | $-2.09 | -63.46% |
| 2016 | $-5.72 | 126.98% |
| 2015 | $-2.52 | 34.04% |
| 2014 | $-1.88 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | 1,319.67% |
US
|
|
| $-7.98 | -754.10% |
US
|
|
| $-5.29 | -533.61% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 2,173.77% |
NL
|
